Clinical Trials · NCT03423199
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- National Cancer Center, Japan
- Enrollment
- 180
- Start date
- Feb 2018
- Locations
- 23 sites, 4 countries
- Primary endpoint
- Progression-free survival (PFS)